Reviewing Cartesian Growth Co. II (NASDAQ:RENE) & Moolec Science (NASDAQ:MLEC)

Cartesian Growth Co. II (NASDAQ:RENE) and Moolec Science (NASDAQ:MLEC) are both small-cap unclassified companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Profitability

This table compares Cartesian Growth Co. II and Moolec Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Growth Co. II	N/A	-51.08%	5.43%
Moolec Science	-129.97%	-97.95%	-27.91%

Valuation & Earnings

This table compares Cartesian Growth Co. II and Moolec Science”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Growth Co. II	N/A	N/A	$11.44 million	N/A	N/A
Moolec Science	$5.62 million	5.86	-$7.31 million	($0.20)	-4.29

Cartesian Growth Co. II has higher earnings, but lower revenue than Moolec Science.

Insider and Institutional Ownership

59.0% of Cartesian Growth Co. II shares are owned by institutional investors. Comparatively, 0.1% of Moolec Science shares are owned by institutional investors. 26.6% of Cartesian Growth Co. II shares are owned by insiders. Comparatively, 19.9% of Moolec Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Cartesian Growth Co. II has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Moolec Science has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cartesian Growth Co. II and Moolec Science, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Growth Co. II	0	0	0	0	0.00
Moolec Science	0	0	1	0	3.00

Moolec Science has a consensus price target of $6.00, indicating a potential upside of 600.12%. Given Moolec Science’s stronger consensus rating and higher probable upside, analysts plainly believe Moolec Science is more favorable than Cartesian Growth Co. II.

Summary

Cartesian Growth Co. II beats Moolec Science on 7 of the 11 factors compared between the two stocks.

About Cartesian Growth Co. II

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.